share_log

上海医药(601607.SH):终止B001、B001-A、I022(联合用药、乳腺癌一线治疗)以及I022-K四个研发项目的临床试验及后续开发

Sh Pharma (601607.SH): Terminated clinical trials and subsequent development of four research and development projects including B001, B001-A, I022 (combination therapy, first-line treatment of breast cancer) and I022-K.

Gelonghui Finance ·  Jun 7 04:20

Sh Pharma (601607.SH) announced that based on comprehensive evaluation of the future market value of research and development projects, business synergy, and subsequent development inputs, B001, B001-A, I022 (combination therapy, first-line treatment of breast cancer) and I022-K four R&D projects' clinical trials and subsequent development were terminated. Among them, B001 was in the end stage of Phase I clinical trial, B001-A project received a clinical trial approval notice, but no clinical trial was conducted afterwards; I022-K project was in the end stage of Phase I clinical trial; I022 project (combination therapy, first-line treatment of breast cancer) was in the end stage of Phase II clinical trial.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment